Samsung Biologics will acquire PolyPeptide Group via an all‑cash public tender offer valued at SFr1.46 billion (approximately $1.81 billion).
The tender offer price is SFr44.31 per share for 100 % of PolyPeptide’s fully diluted share capital, excluding treasury shares.
The transaction is expected to close by the end of the year, subject to reaching a minimum acceptance threshold of roughly 67 %, securing necessary regulatory approvals, and fulfilling other requirements under Swiss takeover legislation.
PolyPeptide’s board, acting through its independent and non‑conflicted members, unanimously recommends that shareholders accept the tender offer, on the terms to be detailed in the forthcoming prospectus.
The largest shareholder, holding approximately 55.65 % of outstanding shares (excluding treasury shares), has given an irrevocable undertaking to tender its shares in the offer.
Samsung Biologics aims to broaden its capabilities beyond antibodies and antibody‑drug conjugates (ADCs) through this acquisition, targeting the expanding market for peptide‑based therapeutics.
PolyPeptide maintains manufacturing facilities in Belgium, France, India, Sweden, and the United States, together with a corporate headquarters in Switzerland and an Innovation Centre in France.
The firm specializes in peptide‑based active pharmaceutical ingredients and has developed over 1,000 therapeutic peptides throughout its history.
John Rim, CEO and Chairman of Samsung Biologics’ Board, stated, “This acquisition reinforces our long‑term growth strategy by expanding our service portfolio into peptide modalities such as GLP‑1 and by strengthening our geographic presence across the U.S., Europe, and India.”
We highly value PolyPeptide’s world‑class workforce, leading expertise, and global operational footprint, and look forward to combining the complementary strengths of both companies to support our continued growth as a premier CDMO for clients in the years ahead.
The offer represents a 40 % premium to PolyPeptide’s last undisturbed share price on April 10, 2026, and about an 11.6 % premium to the 60‑day volume‑weighted average price.
Upon completion, Samsung Biologics intends to acquire all remaining shares and delist PolyPeptide from the SIX Swiss Exchange. JP Morgan acts as the exclusive financial adviser to Samsung Biologics.
Ernst & Young Han Young serves as accounting and tax adviser, while O’Melveny & Myers and Schellenberg Wittmer provide legal counsel.
